Cargando…
Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis
Despite considerable advances in the treatment of multiple sclerosis, current drugs are only partially effective. Most patients show reduced disease activity with therapy, but still experience relapses, increasing disability, and new brain lesions. Since there are no reliable clinical or biological...
Autores principales: | Hecker, Michael, Paap, Brigitte Katrin, Goertsches, Robert Hermann, Kandulski, Ole, Fatum, Christian, Koczan, Dirk, Hartung, Hans-Peter, Thiesen, Hans-Juergen, Zettl, Uwe Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246503/ https://www.ncbi.nlm.nih.gov/pubmed/22216338 http://dx.doi.org/10.1371/journal.pone.0029648 |
Ejemplares similares
-
Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance
por: Hundeshagen, Alexander, et al.
Publicado: (2012) -
Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
por: Thamilarasan, Madhan, et al.
Publicado: (2013) -
Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study
por: Frahm, Niklas, et al.
Publicado: (2019) -
Integrative modeling of transcriptional regulation in response to antirheumatic therapy
por: Hecker, Michael, et al.
Publicado: (2009) -
MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients
por: Hecker, Michael, et al.
Publicado: (2013)